

Zelira Therapeutics Ltd

09:33 10 Oct 2018

Zelda Therapeutics begins observational trial for medicinal cannabis treatment of autism

Zelda Therapeutics Ltd (ASX:ZLD) (OTCMKTS:ZLDAF) (FRA:G1G) has started recruitment for an autism observational trial in the USA centred on medicinal cannabis treatment.

Fifteen patients have been formally enrolled and first results are expected in the first half of 2019.

The trial, which is seeking to better understand the efficacy of medicinal cannabis treatment in existing patients, is being carried out at Children's Hospital of Philadelphia (CHOP) in the USA.

"Diagnosis rates on the rise"

Zelda and CHOP will work closely with patient advocacy groups during the trial.

The company's managing director Dr Richard Hopkins said, "We are excited to have this study underway and to be working alongside CHOP to conduct one of the first formal, robust studies of its type in the world.

"With studies showing that around one in 100 people have autism and with diagnosis rates on the rise, we're focused on addressing a major unmet need for potential new therapies to help treat this condition."

The study will utilise CHOP's extensive research infrastructure and is designed to capture a number of key efficacy and safety measures, including clinical pharmacological data using a novel micro-sampling technique developed by CHOP.

Pediatric patients already being treated with medicinal cannabis formulations will be monitored.

Possible future clinical trial

It will lay the groundwork for a possible future clinical trial to generate high-quality, robust and acceptable data to validate the existing anecdotal data amongst patient populations.

The ultimate goal is to identify cannabinoid-based compounds that may demonstrate efficacy in the treatment of pediatric autism.

Developing cannabinoid-based formulations

Zelda is an Australian-based bio-pharmaceutical company focused on developing a range of cannabinoid-based formulations for the treatment of a

Price: 0.058

Market Cap: \$56.05 m

1 Year Share Price Graph



Share Information

Code: ZLD

Listing: ASX

52 week High Low
0.091 0.022

Sector: Cannabis

Website: www.zeldatherapeutics.com

Company Synopsis:

Zelira Therapeutics Ltd (ASX:ZLD) is a medicinal cannabis company focused on first-in-class human clinical trials for insomnia, autism and opioid reduction.

action@proactiveinvestors.com.au

variety of medical conditions.

The company has a two-armed strategy comprising:

- A human clinical trial program focused on insomnia and autism with activities in Australia, Chile and the USA.
- A pre-clinical research program examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

READ: Zelda Therapeutics doses first patient in insomnia clinical trial

The company recently dosed the first patient in its medical cannabis insomnia clinical trial with results expected in the first half of 2019.

A randomised, placebo-controlled, crossover study design will be used to treat 24 patients with Zelda's medicinal cannabis formulation.

The study will collect and analyse data to determine the effect of the formulation on the time it takes to fall asleep, time spent awake and asleep during the night and quality of sleep.

READ: Zelda Therapeutics enters German medical cannabis market with partnership

Another recent development has been a distribution and manufacturing strategic partnership with German medicinal cannabis group HAPA Medical.

Under this arrangement, HAPA has first rights to distribute and/or manufacture Zelda's clinically validated formulations into the rapidly growing German market.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).